VANFLYTA 17.7 mg/1
QUIZARTINIB · TABLET, FILM COATED · Daiichi Sankyo Inc.
Vanflyta (quizartinib) is an oral tablet used to treat adults with acute myeloid leukemia that has a specific genetic mutation. It works by blocking certain proteins that help leukemia cells grow.
Key Facts
- Brand Name
- VANFLYTA
- Generic Name
- QUIZARTINIB
- NDC Code (Product)
65597-504- Manufacturer
- Daiichi Sankyo Inc.
- Strength
- 17.7 mg/1
- Dosage Form
- TABLET, FILM COATED
- Route
- ORAL
- Marketing Status
- Application #
- NDA216993
- Marketing Start
- 07/20/2023
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is VANFLYTA used for?
Vanflyta (quizartinib) is an oral tablet used to treat adults with acute myeloid leukemia that has a specific genetic mutation. It works by blocking certain proteins that help leukemia cells grow.
Is VANFLYTA a controlled substance?
VANFLYTA is not classified as a controlled substance by the DEA.
What is the generic name for VANFLYTA?
The generic name for VANFLYTA is QUIZARTINIB. There are no other listed brand versions of QUIZARTINIB.
What is the NDC code for VANFLYTA 17.7 mg/1?
The NDC (National Drug Code) for VANFLYTA 17.7 mg/1 is 65597-504, listed by Daiichi Sankyo Inc..
Other VANFLYTA Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)